Full-Time

Digital Asset Librarian

Updated on 8/17/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Bachelor's

Category
Medical, Clinical & Veterinary (1)
Required Skills
SharePoint
Adobe InDesign
Microsoft Office
Adobe Creative Suite
Adobe Photoshop
Adobe After Effects
Adobe Premiere Pro
Visio
Word/Pages/Docs
Version Control
Adobe Illustrator
Video Editing
Graphic Design
Excel/Numbers/Sheets
Microsoft Outlook
PowerPoint/Keynote/Slides

Get referred to Amgen

See people who can refer or advise you

Requirements
  • Fluency with Veeva PromoMats and RIM.
  • Proficiency in Veeva digital asset management systems and experience handling file types, metadata, licensing agreements, and usage rights.
  • Strong knowledge of Adobe Creative Suite, including Photoshop, Illustrator, and InDesign; Premiere Pro; After Effects; and other design tools.
  • Proficiency in Microsoft Office Suite, including PowerPoint, Visio, Excel with pivot tables, and Word.
  • Familiarity with digital asset management best practices, including asset tagging, archiving, and retrieval within Veeva, SharePoint, and Box.
  • Understanding of Veeva workflows for initiating, reviewing, approving, and routing materials through lifecycle stages.
  • Hands-on experience navigating Veeva PromoMats and RIM to manage promotional and medical content.
  • Experience performing quality-control checks on submitted materials for compliance with United States regulatory, legal, and brand standards.
  • Ability to update and maintain metadata accurately within Veeva PromoMats and RIM, including naming conventions, taxonomy, and version control.
  • Knowledge of compliance and United States Food and Drug Administration regulatory requirements for promotional materials in the pharmaceutical or life sciences industry.
  • Experience troubleshooting and resolving metadata or workflow issues in collaboration with Regulatory, Marketing, and creative-agency teams.
  • Ability to identify discrepancies and ensure data integrity across documents and metadata fields.
  • Ability to manage multiple tasks and priorities within tight deadlines in a fast-paced, highly regulated environment.
  • Ability to communicate with stakeholders and provide guidance on Veeva PromoMats processes and best practices.
  • Proven ability to manage multiple projects simultaneously while meeting deadlines and following established processes.
  • Microsoft Outlook inbox-management skills, including organizational methods, email rules, and standard email templates.
  • Ability to develop and maintain structured process documents, standard operating procedures, and workflow guides.
  • Ability to design and run periodic and ad hoc reports using Veeva reporting functionality to support leadership analysis and interpretation of performance data.
Responsibilities
  • Evaluate creative-file submissions and system metadata for completeness, accuracy, and licensing compliance.
  • Collaborate with creative agencies and marketing teams to renegotiate, renew, and collect usage rights for marketing materials.
  • Use company subscriptions to provide art-procurement services supporting marketing initiatives.
  • Retrieve, validate, and distribute digital-asset packages to agencies and marketing teams using company data repositories.
  • Facilitate and participate in stakeholder meetings to ensure adherence to digital asset management timelines and processes.
  • Maintain and manage records in Veeva and SharePoint.
  • Lead and facilitate Webex and Microsoft Teams meetings, including agenda preparation and accurate meeting-minute documentation.
  • Create infographics and presentation materials.
  • Perform technical editing and proofreading of process documentation.
Desired Qualifications
  • A bachelor's degree in graphic design, visual arts, marketing, or a related creative field.
  • At least two years of experience in the marketing, pharmaceutical, or healthcare industries, with a strong understanding of creative design for promotional materials.
  • Experience collaborating with creative agencies and cross-functional teams to facilitate collection, transfer, and distribution of marketing materials.
  • Ability to conduct thorough quality-control checks on creative files for promotional content.
  • Understanding of Food and Drug Administration regulations and compliance requirements related to marketing materials and submissions.
  • Strong analytical and problem-solving skills for digital-asset retrieval, file troubleshooting, validation, and distribution.
  • Communication and stakeholder-management skills for leading and participating in discussions about digital asset management timelines and creative-file submission approvals.
  • Prior experience with SharePoint and Veeva Business Administrator certification.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 10% to $10.1 billion; guidance increased to $38.2-$39.4 billion.
  • Repatha grew 37%, Evenity 38%, and Uplizna 90% in Q2 2026.
  • Colorado’s Enbrel price cap was blocked on July 1, 2026, preserving legacy cash flow.

What critics are saying

  • FDA proposed Tavneos withdrawal on April 27, 2026; a hearing loss kills ChemoCentryx economics.
  • Tavneos retraction and liver-injury findings threaten Amgen’s credibility with regulators and investigators in 2026.
  • Prolia erosion and patent battles, including Delaware’s June 2026 verdict, pressure margins until 2027.

What makes Amgen unique

  • MariTide’s monthly-to-quarterly dosing targets obesity convenience versus weekly GLP-1 rivals in 2027.
  • Amgen’s 2026 base is unusually diversified: Repatha, Evenity, Uplizna, Tezspire, and Imdelltra.
  • Amgen’s 2027 Hyderabad Science and Innovation Center expands AI-linked discovery capacity globally.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Aug 14th, 2026
Amgen and Regeneron emerge as GLP-1 investment alternatives beyond Eli Lilly and Novo Nordisk

Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.

PR Newswire
Aug 12th, 2026
Amgen to open new science and innovation centre in Hyderabad's Genome Valley

Amgen announced plans to open a new Science and Innovation Center in Genome Valley, Hyderabad, expected to be operational in 2027. The facility will join Amgen's global Research and Development network of seven research laboratories, expanding the company's scientific capabilities. The center will bring together scientists and technologists across discovery chemistry, drug metabolism and pharmacokinetics, and precision medicine. It will integrate experimental science with data and digital innovation to accelerate the discovery and development of medicines. "The new center in Genome Valley expands the way we integrate experimental science with data and technology across our global research capabilities," said Jay Bradner, executive vice president of Research and Development, Artificial Intelligence and Data at Amgen. The facility will complement Amgen's existing technology and innovation site in Hyderabad.

Yahoo Finance
Aug 9th, 2026
Amgen fair value rises to $372 after Q2 beat sparks analyst target hikes to $450

Amgen's modeled fair value has risen from $352.23 to $371.93 per share following strong Q2 results and updated analyst targets. Several firms, including Scotiabank, TD Cowen, BMO Capital, and Oppenheimer, lifted price targets to around $450, citing earnings revisions and a diversified product portfolio. Bernstein noted a 6.8% revenue beat and 12.5% non-GAAP EPS beat in Q2, with raised full-year guidance driven by portfolio-wide execution. Strength came from products including Repatha, Tezspire, Uplizna, Evenity, and Imdelltra. However, Wells Fargo and Citi maintain cautious stances with Equal Weight and Neutral ratings, suggesting current performance may already be priced in. BofA kept its Underperform rating, describing 2026 as focused on execution ahead of key 2027 readouts.

Yahoo Finance
Aug 5th, 2026
Amgen beats Q2 forecast with $10.05B revenue, raises 2026 outlook despite obesity drug setback

Amgen reported second-quarter revenue of $10.05 billion, up 9% year on year, beating Wall Street expectations. Adjusted earnings reached $6.29 per share, surpassing the $5.62 consensus estimate. The biotech firm raised its full-year 2026 outlook, increasing expected revenue to $38.2 billion-$39.4 billion from $37.0 billion-$38.4 billion. Adjusted earnings guidance rose to $22.30-$23.50 per share. Repatha sales surged 37% to $953 million, whilst Evenity jumped 38% to $714 million. Rare-disease therapy Uplizna saw roughly 90% growth. These gains offset a 32% decline in Prolia sales due to biosimilar competition. Amgen discontinued obesity candidate AMG 513 but continues developing MariTide, with Phase 3 data expected in 2027. The stock trades at $406.17, approximately 14.75% above its estimated fair value.

PR Newswire
Aug 4th, 2026
Amgen reports 10% revenue growth to $10.1B in Q2 2026, driven by 26% surge in six key growth products

Amgen reported second quarter 2026 revenues of $10.1 billion, a 10% increase year-over-year. Product sales grew 9%, driven by volume growth across 22 products that achieved double-digit sales growth. The company's six key growth drivers grew 26% year-over-year, generating nearly 70% of second quarter product sales. GAAP earnings per share increased 65% to $4.37, whilst non-GAAP EPS rose 4% to $6.29. Notable product performance included Repatha sales increasing 37% to $953 million and EVENITY growing 38% to $714 million. The company generated $3.5 billion in free cash flow, compared to $1.9 billion in the prior year period. For full year 2026, Amgen expects total revenues between $38.2 billion and $39.4 billion, with non-GAAP EPS guidance of $22.30 to $23.50.